Female sex, anti-CTLA\u20104 therapy, and anti-PD\u20101 therapy linked to better overall survival, while worse survival seen with hepatic metastases<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, July 12, 2023 (HealthDay News) — Factors associated with improved survival in metastatic uveal melanoma include female sex and use of anti-cytotoxic T lymphocyte-associated antigen (CTLA)-4 and anti-programmed cell death protein 1 (PD-1) therapies, according to research published online June 29 in Cancer<\/em>.<\/p>\n Patrick Demkowicz, from the Yale University School of Medicine in New Haven, Connecticut, and colleagues conducted a retrospective review of metastatic uveal melanoma patients at Yale (initial cohort) and Memorial Sloan Kettering (validation cohort). Eighty-nine patients were identified, including 71 and 18 in the initial and validation cohorts, respectively.<\/p>\n The researchers found better survival outcomes in association with female sex, anti-CTLA-4 therapy, and anti-PD-1 therapy, with adjusted hazard ratios for death of 0.40, 0.44, and 0.42, respectively; development of hepatic metastases and Eastern Cooperative Oncology Group (ECOG) Performance Status Scale score \u00e2\u0089\u00a51 were associated with worse survival (hazard ratios, 2.86 and 2.84, respectively). After adjustment for sex and ECOG score, use of immune checkpoint inhibitors was associated with improved overall survival, with hazard ratios for death of 0.22 and 0.04, respectively.<\/p>\n “Metastatic uveal melanoma patients face limited treatment options and poor survival rates,” the authors write. “Our findings suggest that immune checkpoint inhibitors may provide a viable treatment option for patients with metastatic uveal melanoma.”<\/em><\/p>\n